Meros Equity
Personal Account
Gracell Biotechnologies
IPO GRCL.NASDAQ Past

Gracell Biotechnologies

Developer of cancer immune therapy designed to treat cancer

Company website
Ticker

GRCL.NASDAQ

Market

us

Foundation year

2017

Close date

2/10/2021

IPO date

1/7/2021

Placement price

$19

Profitability

54.95%

About

Total Funding 

$185M

Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer. The company's therapy offers cellular therapeutics for the patients suffered from hematological malignancy, solid tumor or degenerative disease, enabling healthcare providers to cure their patients and improve their lives.

Number of employees

51-100

Headquarters

Suzhou, Jiangsu, China

Meros Equity

2022 © All rights reserved

You can always come to our office to discuss any questions with our manager

Dubai

Sharjah Media City, Sharjah, UAE

USA

500 Delaware ave,
STE 1 #1960 Wilmington, DE, USA

Czech Republic

Czech Republic, Prague, Bilkova 855/19

The investment opportunities posted on this website's Pre-IPO section are private placements of securities that are not traded on the open market, subject to the ownership period requirements, and intended for investors who do not require liquid investments. Investments in private companies may be considered speculative, involving high risk, including the significant loss of investment risk. Investors must be able to afford to lose all their investments.